title: Patient characteristics and intravenous immunoglobulin product may affect eosinophils in Kawasaki disease.
authors.forename: Ho-Chang
authors.initials: HC
authors.lastname: Kuo
authors.forename: Chih-Lu
authors.initials: CL
authors.lastname: Wang
authors.forename: Lin
authors.initials: L
authors.lastname: Wang
authors.forename: Hong-Ren
authors.initials: HR
authors.lastname: Yu
authors.forename: Kuender D
authors.initials: KD
authors.lastname: Yang
mesh_terms: D015703:Antigens, CD / Q000276:immunology; D000944:Antigens, Differentiation, B-Lymphocyte / Q000276:immunology; D001323:Autoantibodies / Q000009:adverse effects / Q000097:blood; D015415:Biomarkers / Q000097:blood; D004802:Eosinophilia / Q000139:chemically induced* / Q000150:complications; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000009:adverse effects*; D037102:Lectins / Q000276:immunology; D009080:Mucocutaneous Lymph Node Syndrome / Q000150:complications / Q000188:drug therapy* / Q000276:immunology*
chemical_list: D015703:Antigens, CD; D000944:Antigens, Differentiation, B-Lymphocyte; D001323:Autoantibodies; D015415:Biomarkers; D016756:Immunoglobulins, Intravenous; D037102:Lectins; C403967:SIGLEC8 protein, human